

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

MYLAN PHARMACEUTICALS INC.,  
Petitioner

v.

ALLERGAN, INC.,  
Patent Owner

---

Case IPR2016-01128  
Patent 8,629,111

---

**DECLARATION OF ERIC RUBINSON**

I, Eric Rubinson, declare and certify as follows:

1. I am Executive Director, DDO Business Operations at Allergan, Inc. (“Allergan”).

2. I make this declaration based on my personal knowledge.

3. I have been employed with Allergan for 11 years.

4. Attached hereto as Exhibit A is an Interoffice Memorandum dated October 29, 1998 titled “Pharmacokinetics and Drug Metabolism Report PK-98-074.”


5. Exhibit A is a true and accurate copy of the original document.

6. I have personal knowledge of Allergan’s regularly conducted business practices and activities for creating, recording, maintaining, and storing information and documents. The regular practice of Allergan when creating a record of an act, event, condition, or information is for an employee or representative of Allergan with knowledge of the respective act, event, condition, or information to make the record or to transmit the information to be included in the record at or near the time of the act, event, condition, or information gathering or reasonably soon thereafter.

7. The document attached as Exhibit A is a copy of an original document that was created and kept by Allergan in the course of its regularly conducted business practices and activities.

I declare under penalty of perjury under the laws of the United States of America that the foregoing declaration is true and correct.

Executed on: March 17, 2017



17-MARCH-2017

Eric Rubinson  
Executive Director, DDO Business Operations  
Allergan, Inc.  
Harborside Financial Center, Plaza V  
Jersey City, NJ 07311

# EXHIBIT A

## Table of Contents

PK-98-074 .....	3
Title Page .....	3
Signature Page .....	3
Statement Of Compliance .....	4
Summary .....	5
Key Words .....	5
Introduction .....	6
Materials and Methods .....	6
Chemical and Reagents .....	6
Test Articles .....	6
Formulation Manufacture .....	7
Formulation Analysis .....	7
Animals .....	8
Experimental .....	9
Tissue Bioanalysis .....	9
Data Analysis .....	10
Data and Report Handling and Storage .....	10
Protocol Deviations .....	10
Results and Discussion .....	11
Formulations .....	11
Animals .....	11
Bioanalysis .....	12
Tissue Concentrations and Pharmacokinetic Parameters .....	12
Conclusions .....	14
References .....	14
Tables .....	16
Table I. Study Design and Formulation and Dosing Data for Ocular and Systemic Absorption of Radioactivity in Rabbits... ..	16
Table II. Results of Predose, Interim, and Postdose 3H-Cyclosporine Formulation Analyses .....	17

Table III. Tissue Sample Masses from Dosed Rabbits and Limits of Quantitation (LPQ) of 3H-Radioactivity in Sampled Tissues .....	18
Table IV. Ocular Tissue Concentrations (n=4) in Albino Rabbits after 9 1/2 Days of Twice-Daily Ophthalmic Instillation of ... ..	19
Table V. Ocular Tissue Concentrations (n=4) in Albino Rabbits after 9 1/2 Days of Twice-Daily Ophthalmic Instillation of... ..	20
Table VI. Ocular Pharmacokinetic Parameters of 3H-Radioactivity in Albino Rabbits after 9 1/2 Days of Twice-Daily... ..	21
Table VII. Ocular Pharmacokinetic Parameters of 3H-Radioactivity in Albino Rabbits after 9 1/2 Days of Twice-Daily... ..	22
Table VIII. Ocular Pharmacokinetic Ratios in Specific Tissues after b.i.d. Instillation of 0.05% and 0.1% CsA Emulsions... ..	23
Table IX. Ocular Pharmacokinetic Parameters of Total Radioactivity in Albino Rabbits after Instillation of a Single Dose ... ..	24
Figures .....	25
Figure 1. Concentrations in Albino Rabbit Tears (top) and Lacrimal Gland (bottom) after 9 1/2 Days of Twice Daily... ..	25
Figure 2. Concentrations in Albino Rabbit Upper (top) and Lower (bottom) Conjunctiva after 9 1/2 Days of Twice Daily... ..	26
Figure 3. Concentrations in Albino Rabbit Cornea (top) and Sclera (bottom) after 9 1/2 Days of Twice Daily Ophthalmic... ..	27
Figure 4. Concentrations in Albino Rabbit Aqueous Humor (top) and Iris-Ciliary Body (bottom) after 9 1/2 Days of Twice... ..	28
Figure 5. Concentrations in Albino Rabbit Lens (top) and Vitreous Humor (bottom) after 9 1/2 Days of Twice Daily... ..	29
Figure 6. Concentrations in Albino Rabbit Choroid-Retina after 9 1/2 Days of Twice Daily Ophthalmic Instillation of 0.05... ..	30
Inspection Statement .....	31

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.